drugset / Trial / NCT04927585
Evaluating the Safety and Immunogenicity of Polyvalent DNA/gp120 HIV Vaccine in Healthy, HIV-uninfected Adults
Phase 1
Completed
42 enrolled
Worcester HIV Vaccine
Access to Advanced Health Institute (AAHI) · collabBrigham and Women's Hospital · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
The purpose of the study is to evaluate the safety, tolerability, and immunogenicity of polyvalent env (A,B,C,A/E)/gag (C) DNA and gp120 (A,B,C,A/E) protein vaccines (PDPHV201401) co-administered together with or without adjuvant in repeated doses in healthy, HIV-uninfected adults
Timeline
- Start
- 2021-07-08
- Primary completion
- 2023-12-07
- Completion
- 2023-12-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GLA-SE | Other / unclassified | — | Intramuscular |
| Subject | env (A,B,C,A/E)/gag (C) DNA Vaccine | Vaccine | 2 mg | Intramuscular |
| Subject | gp120 (A,B,C,A/E) Protein Vaccine | Vaccine | 400 ug | Intramuscular |